Top Page
InnoCan Pharma
(OTC:INNO)
InnoCan Pharma (INNO) vs. S&P 500 (SPY)
InnoCan Pharma Business Overview & Revenue Model
InnoCan Pharma Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 28.93M | 13.66M | 2.56M | 196.00K | 8.00K | 0.00 | Gross Profit |
| 26.07M | 11.98M | 2.11M | 121.00K | 3.00K | 0.00 | EBIT |
| -1.22M | 3.80M | -6.27M | -7.48M | -4.72M | -3.00M | EBITDA |
| -836.00K | -3.77M | -3.85M | -10.04M | -9.90M | -2.98M | Net Income Common Stockholders |
| -2.60M | -4.70M | -3.89M | -10.06M | -15.18M | -3.67M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 214.00K | 3.88M | 4.95M | 11.05M | 2.34M | 1.97M | Total Assets |
| 660.00K | 6.94M | 6.98M | 12.57M | 4.33M | 2.58M | Total Debt |
| 0.00 | 33.00K | 34.00K | 1.00K | 38.00K | 72.00K | Net Debt |
| -214.00K | -3.85M | -4.91M | -11.05M | -2.30M | -1.90M | Total Liabilities |
| 533.00K | 2.55M | 751.00K | 3.56M | 7.94M | 1.17M | Stockholders Equity |
| 127.00K | 4.10M | 6.39M | 9.05M | -3.61M | 1.41M |
| Cash Flow | Free Cash Flow | ||||
| -2.41M | -3.95M | -6.09M | -6.67M | -3.69M | -2.72M | Operating Cash Flow |
| -2.39M | -3.90M | -6.07M | -6.63M | -3.69M | -2.71M | Investing Cash Flow |
| -20.00K | -84.00K | -31.00K | -48.00K | 0.00 | -9.00K | Financing Cash Flow |
| 3.42M | 2.92M | 125.00K | 15.30M | 4.02M | 4.45M |
InnoCan Pharma Technical Analysis
InnoCan Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$979.28M | 17.25 | 3.80% | ― | 35.87% | ― | |
58 Neutral | C$60.26M | ― | -55.06% | ― | 195.68% | 50.94% | |
51 Neutral | $1.08B | ― | -23.33% | ― | 0.67% | 19.14% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
32 Underperform | $257.15M | ― | -84.50% | ― | -16.27% | 76.17% |
InnoCan Pharma Corporate Events
Innocan Pharma’s subsidiary, BI Sky Global, has completed the Human Repeated Insult Patch Test (HRIPT) for its cosmetic products, ensuring their safety. Additionally, the company has achieved a significant sales milestone by selling an average of 5,000 units per day in 2024, far exceeding the typical production quantities in the cosmetics industry. This accomplishment highlights Innocan’s robust market presence and the potential for further expansion, delivering considerable value to shareholders.
Innocan Pharma has been granted a sponsor fee waiver by the FDA’s Center for Veterinary Medicine for its LPT-CBD product for the second consecutive year. This waiver, under the Animal Drug User Fee Act, recognizes Innocan’s commitment to innovative animal drug development. The LPT-CBD product is designed to manage chronic pain in dogs through precise and sustained CBD release from a single injection, addressing a significant market need among pet owners. The waiver accelerates Innocan’s efforts to deliver this innovative solution, highlighting the company’s progress and potential impact in the veterinary pharmaceutical industry.
InnoCan Pharma has successfully closed a private placement, raising C$635,444.60 through the issuance of 3,177,223 units. The funds will be used to advance its CBD-loaded liposome platform technology and support consumer wellness operations. This move signals strong investor confidence in the company’s strategic direction and innovative offerings.
Innocan Pharma is set to raise up to C$700,000 through a private placement of units, with each unit consisting of one common share and one warrant. The funds will be directed towards working capital and corporate purposes, as the company continues to innovate in the pharmaceuticals and wellness sectors.
InnoCan Pharma has made notable strides in 2024, achieving key regulatory milestones for its liposome-cannabidiol (LPT-CBD) technology, aimed at chronic pain treatment. The company’s advancements, including FDA recognition and a streamlined development pathway, are expected to accelerate market entry and address unmet needs in both human and veterinary medicine.
Innocan Pharma has announced promising results from a safety assessment of its LPT-CBD injectable on minipigs, showing excellent tolerance and no adverse effects. This study supports the feasibility of LPT-CBD’s safety evaluations, paving the way for future regulatory milestones in chronic pain treatment.
Innocan Pharma has reported impressive financial results for the third quarter of 2024, with a 174% year-over-year increase in 9-month revenues to $24 million, primarily driven by its subsidiary BI Sky Global Ltd. The company has also turned its financial performance around, achieving a net profit of $0.3 million compared to a net loss in the previous year, showcasing strong operational momentum and successful product introductions.
Innocan Pharma is shifting its focus towards its Liposome Platform Technology-Cannabidiol (LPT-CBD) after receiving encouraging progress from the FDA, targeting the booming veterinary market. With the U.S. pet industry projected to reach $156 billion in 2024, Innocan aims to capture the growing demand for effective chronic pain treatments for animals. The company has decided to conclude its Cannabinoid-Loaded Exosome (CLX) project to better allocate resources towards the promising LPT-CBD platform.